

Special Issue

Timely Administration of the Hepatitis B Birth Dose Vaccine

Message from the Guest Editors

To achieve the WHO's objective to globally eliminate hepatitis B virus (HBV) infection by 2030, it is essential to prevent mother-to-child transmission of HBV. Administration of the hepatitis B vaccine to neonates, preferably within 24 hours after birth, is a key intervention recommended by the WHO to reach this goal. However, the timely administration of the hepatitis B birth dose vaccine (HepB-BD) has not been well implemented in low- and middle-income countries for multiple reasons, including a high rate of childbirth at home. This Special Issue aims to uncover the current situation of the implementation of the HepB-BD, the challenges and facilitators for its timely administration, and potential innovations to overcome these problems. This Special Issue welcomes the submission of papers from a wide range of disciplines including basic science, clinical/epidemiological research, social/anthropological studies, and health economy.

Guest Editors

Dr. Yusuke Shimakawa

Unité d'Epidémiologie des Maladies Emergentes, Institut Pasteur,
75015 Paris, France

Dr. Youkyung Choi

Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis,
STD and TB Prevention, The Centers for Disease Control and
Prevention, Atlanta, GA 30329, USA

Deadline for manuscript submissions

closed (31 March 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/49084

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).